Compound ID | 3393
LMN-101
Synonym(s): LMN101 | LMN 101
Class: Antibody
| Agent Type: | Indirect acting; Antibody; |
| Spectrum of activity: | Gram-negative |
| Target Pathogen: | Active against Enterobacterales; intended indication for enterotoxigenic E. coli infection/ traveller's diarrhoea |
| Description: | Nanobody derived from IgG antibodies in Camelidae family |
| Institute where first reported: | Lumen Bioscience |
| Year first mentioned: | 2019 |
| Highest development stage: | Phase 2 (NCT04182490) |
| Development status: | Active |
| External links: | |
| Citation: | https://clinicaltrials.gov/study/NCT04182490?term=LMN-101&rank=1 |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.